Multiple Sclerosis with demyelination. (Shutterstock Image)
Multiple sclerosis (MS) disrupts the nerves’ ability to transmit signals around the body. MS can make it hard to walk or hold a pen, for example. The problem is caused by inflamed and degenerating insulation around the nerves, called myelin. Just like a wire with frayed insulation, nerves with damaged myelin can short out or pick up stray signals. Fortunately, most people with MS have long periods of remission, when they recover and can walk and live as they did before developing the disease.
But eventually, most people with MS develop progressive disease, in which their symptoms get steadily worse. And some people actually start out with progressive disease, called primary progressive MS.
Currently, there is only one drug for progressive disease, and it slows the progression but does not halt it.
UConn Health neuroscientist Stephen Crocker wants to better understand progressive MS so that new treatments might be found. In the past, he and his colleagues had shown that the brain stem cells from people with primary progressive MS prevents oligodendrocytes, the cells that form myelin, from maturing. It’s something the brain stem cells are doing, and it was likely why people with primary progressive MS never have remissions – the insulation around their nerve cells never gets repaired.
Now, Crocker and his colleagues report that brain stem cells from primary progressive MS patients look prematurely old. Brain stem cells examined by neurologist Anna Williams at the University of Edinburgh, Valentina Fossati at the New York Stem Cell Foundation, and Crocker’s lab all looked to be decades older than otherwise similar cells from healthy people of the same age, as judged by standard cell age markers.
And the team found that not only do the brain stem cells from primary progressive MS patients look older – they also act older. An analysis done as part of the study by Paul Robson at the UConn–Jackson Laboratory for Genomic Medicine Single Cell Center showed that oligodendrocytes exposed to the patients’ stem cells start expressing different genes. This may explain why the myelin is compromised.
Intriguingly, the research group figured out that many of the genes activated in the oligodendrocytes were being prodded by a specific protein, a protein that the MS patients’ stem cells were producing at high levels. Crocker’s lab demonstrated that when they blocked this protein, HMGB1, the oligodendrocytes then developed normally.
“This protein actively blocks the ability of oligodendrocytes to mature. We did not know that before. It had been found in lesions, and it has been associated with inflammation, but it was thought to be just exciting the immune system. Now we can see that if we block that protein, we dramatically improve the oligodendrocyte’s growth,” Crocker says.
“Primary progressive MS is a devastating disease for which we are still missing effective treatments, and regenerating myelin is a major need that current therapeutics have not met,” says Fossati. “We are excited that the study of human stem cells in a dish led to the discovery of a new disease mechanism that could be targeted in much-needed therapeutics for progressive MS patients.”
“We believe that understanding the differences between brain stem cells from people with MS and those from healthy people will hold vital clues to developing much-needed treatments,” Williams says.
Crocker’s lab also found that treating the brain stem cells with rapamycin helped the cells develop normally. Rapamycin is a drug that can be used to suppress the immune system. It had already been tested in relapsing-remitting MS patients and found not to help. But it might help patients with the progressive form of the disease.
“Recent studies have shown that drugs designed to target aging processes such as senescence may slow the onset and progression of many different chronic diseases, including cancer, atherosclerosis, stroke, and Alzheimer’s disease, for which aging is a major risk factor. This work could have a great impact on the clinical treatment of MS, since it opens up an entirely new direction to explore as a possible approach to slowing the progression of the disease,” says George Kuchel, director of UConn Health’s Center on Aging, who was not involved in the study.
The next step will be to look at brain stem cells from people with the relapsing-remitting form of MS to see if, and when, these changes associated with aging begin. And to see if they can be avoided, slowed, or reversed.
“Brain regenerative therapies are already in clinical trials,” Crocker says, and could potentially be tuned to help regrow the myelin in MS patients’ nervous systems. “We know MS is not a disease of the aged, but it may be a disease of aging. Knowing this, we now want to know how this process can be targeted to enhance myelin repair in patients.”
